CURE SIGNED
Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CURE project word cloud
Explore the words cloud of the CURE project. It provides you a very rough idea of what is the project "CURE" about.
Project "CURE" data sheet
The following table provides information about the project.
| Coordinator |
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Organization address contact info |
| Coordinator Country | Greece [EL] |
| Project website | https://www.cureasthma.eu |
| Total cost | 2˙971˙750 € |
| EC max contribution | 2˙971˙750 € (100%) |
| Programme |
1. H2020-EU.1.2.1. (FET Open) |
| Code Call | H2020-FETOPEN-1-2016-2017 |
| Funding Scheme | RIA |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-10-01 to 2021-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON | EL (ATHINA) | coordinator | 353˙750.00 |
| 2 | THE UNIVERSITY OF MANCHESTER | UK (MANCHESTER) | participant | 1˙128˙000.00 |
| 3 | SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS | CH (DAVOS PLATZ) | participant | 287˙500.00 |
| 4 | UNIVERSYTET MEDYCZNY W LODZI. | PL (LODZ) | participant | 232˙500.00 |
| 5 | GIORGI ELIAVA INSTITUTE OF BACTERIOPHAGY, MICROBIOLOGY AND VIROLOGY | GE (TBILISI) | participant | 222˙500.00 |
| 6 | IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON | EL (ATHINA) | participant | 222˙500.00 |
| 7 | UMEA UNIVERSITET | SE (UMEA) | participant | 217˙500.00 |
| 8 | MARIOS LYMARAKIS KAI SIA EE | EL (GERAKAS ATTIKI) | participant | 135˙000.00 |
| 9 | EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING | BE (Brussels) | participant | 112˙500.00 |
| 10 | ELIAVA BIO PREPARATIONS LTD | GE (TBILISI) | participant | 60˙000.00 |
Map
Project objective
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans. We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
Deliverables
| Website and logo | Websites, patent fillings, videos etc. | 2019-05-31 10:20:03 |
| Variability in space & time | Documents, reports | 2019-05-31 10:20:01 |
| Data Management Plan | Documents, reports | 2019-05-31 10:20:04 |
Take a look to the deliverables list in detail: detailed list of CURE deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Evangelos Andreakos, Ivan Zanoni, Ioanna E Galani Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control published pages: 67-75, ISSN: 0952-7915, DOI: 10.1016/j.coi.2018.10.007 |
Current Opinion in Immunology 56 | 2019-04-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CURE" are provided by the European Opendata Portal: CORDIS opendata.